Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patients-A Pilot Study

Overview

Journal Transpl Int

Specialty General Surgery

Date 2022 Apr 11

PMID 35401042

Authors

Johannes Gokler

Arezu Aliabadi-Zuckermann

Andreas Zuckermann

Emilio Osorio

Robert Knobler

Roxana Moayedifar

Philipp Angleitner

Gerda Leitner

Gunther Laufer

Nina Worel

Affiliations

Soon will be listed here.

Abstract

In severely ill patients undergoing urgent heart transplant (HTX), immunosuppression carries high risks of infection, malignancy, and death. Low-dose immunosuppressive protocols have higher rejection rates. We combined extracorporeal photopheresis (ECP), an established therapy for acute rejection, with reduced-intensity immunosuppression. Twenty-eight high-risk patients (13 with high risk of infection due to infection at the time of transplant, 7 bridging to transplant via extracorporeal membrane oxygenation, 8 with high risk of malignancy) were treated, without induction therapy. Prophylactic ECP for 6 months (24 procedures) was initiated immediately postoperatively. Immunosuppression consisted of low-dose tacrolimus (8-10 ng/ml, months 1-6; 5-8 ng/ml, >6 months) with delayed start; mycophenolate mofetil (MMF); and low maintenance steroid with delayed start (POD 7) and tapering in the first year. One-year survival was 88.5%. Three patients died from infection (POD 12, 51, 351), and one from recurrence of cancer (POD 400). Incidence of severe infection was 17.9% ( = 5, respiratory tract). Within the first year, antibody-mediated rejection was detected in one patient (3.6%) and acute cellular rejection in four (14.3%). ECP with reduced-intensity immunosuppression is safe and effective in avoiding allograft rejection in HTX recipients with risk of severe infection or cancer recurrence.

Citing Articles

The value of extracorporeal photopheresis as an immunosuppression-modifying approach in solid organ transplantation: a potential solution to an unmet medical need.

Augusto J, Benden C, Diekmann F, Zuckermann A Front Immunol. 2024; 15:1371554.

PMID: 38846942 PMC: 11154098. DOI: 10.3389/fimmu.2024.1371554.

References

Berry G, Burke M, Andersen C, Bruneval P, Fedrigo M, Fishbein M . The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013; 32(12):1147-62. DOI: 10.1016/j.healun.2013.08.011. View

Barcia J . Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy. 1998; 18(4):874-6. View

Barr M, Baker C, Schenkel F, McLaughlin S, Stouch B, Starnes V . Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant. 2000; 14(2):162-6. DOI: 10.1034/j.1399-0012.2000.140211.x. View

Mueller N . New immunosuppressive strategies and the risk of infection. Transpl Infect Dis. 2008; 10(6):379-84. DOI: 10.1111/j.1399-3062.2008.00346.x. View

Ladowski S, Abel M, Beatty L, Scatena M, Ladowski J . Long-term follow-up of hearttransplant recipients with pre-transplant malignancies. Tex Heart Inst J. 2006; 33(1):27-30. PMC: 1413611. View

Aliabadi A, Grommer M, Dunkler D, Eskandary F, Salameh O, Gokler J . Impact of Rabbit Antithymocyte Globulin Dose on Long-term Outcomes in Heart Transplant Patients. Transplantation. 2015; 100(3):685-93. DOI: 10.1097/TP.0000000000000950. View

Kirklin J, Brown R, Huang S, Naftel D, Hubbard S, Rayburn B . Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant. 2006; 25(3):283-8. DOI: 10.1016/j.healun.2005.10.004. View

Holdaas H, De Simone P, Zuckermann A . Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. J Transplant. 2016; 2016:4369574. PMC: 5078653. DOI: 10.1155/2016/4369574. View

Stewart S, Winters G, Fishbein M, Tazelaar H, Kobashigawa J, Abrams J . Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005; 24(11):1710-20. DOI: 10.1016/j.healun.2005.03.019. View

10.

Pene F, Pickkers P, Hotchkiss R . Is this critically ill patient immunocompromised?. Intensive Care Med. 2015; 42(6):1051-4. PMC: 7095223. DOI: 10.1007/s00134-015-4161-y. View

11.

Carbone J, del Pozo N, Gallego A, Sarmiento E . Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev Anti Infect Ther. 2011; 9(4):405-13. DOI: 10.1586/eri.10.178. View

12.

Groot O, Trof R, Girbes A, Swart N, Beishuizen A . Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B. Neth J Med. 2008; 66(10):433-7. View

13.

Li H, Yang S, Chen H, Yang Z, Hong T, Hou Y . Survival after heart transplantation for non-metastatic primary cardiac sarcoma. J Cardiothorac Surg. 2016; 11(1):145. PMC: 5048623. DOI: 10.1186/s13019-016-0540-x. View

14.

Chambers D, Cherikh W, Harhay M, Hayes Jr D, Hsich E, Khush K . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1042-1055. PMC: 6816340. DOI: 10.1016/j.healun.2019.08.001. View

15.

Knobler R, Barr M, Couriel D, Ferrara J, French L, Jaksch P . Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol. 2009; 61(4):652-65. DOI: 10.1016/j.jaad.2009.02.039. View

16.

Almenar L, Cardo M, Martinez-Dolz L, Garcia-Palomar C, Rueda J, Zorio E . Risk factors affecting survival in heart transplant patients. Transplant Proc. 2006; 37(9):4011-3. DOI: 10.1016/j.transproceed.2005.09.160. View

17.

Pons S, Sonneville R, Bouadma L, Styfalova L, Ruckly S, Neuville M . Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation. Ann Intensive Care. 2019; 9(1):17. PMC: 6347647. DOI: 10.1186/s13613-019-0490-2. View

18.

Costanzo M, Dipchand A, Starling R, Anderson A, Chan M, Desai S . The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010; 29(8):914-56. DOI: 10.1016/j.healun.2010.05.034. View

19.

Acuna S, Sutradhar R, Kim S, Baxter N . Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study. Transplantation. 2018; 102(7):1156-1164. PMC: 7228636. DOI: 10.1097/TP.0000000000002178. View

20.

Rushton S, Parameshwar J, Lim S, Dar O, Callan P, Al-Attar N . The introduction of a super-urgent heart allocation scheme in the UK: A 2-year review. J Heart Lung Transplant. 2020; 39(10):1109-1117. DOI: 10.1016/j.healun.2020.06.013. View